TMDP

Serotiny Announces a Research Collaboration With Janssen to Optimize Designs for Chimeric Antigen Receptors Signaling Domains

Retrieved on: 
Monday, June 6, 2022
Professional Services, Oncology, Health, Venture Capital, Pharmaceutical, Biotechnology, CA, Mining, Janssen Pharmaceuticals, Chimeric antigen receptor T cell, Protein, Canadian Aviation Regulations, Johnson & Johnson, CAR, TMDP, Machine learning, Technology, Heart, Janssen, Engineering, Synthetic biology, Pharmaceutical industry, Fine chemical, Serotiny

Serotiny, a leader in high-throughput therapeutic Multi-Domain Protein (tMDP) engineering, announced today a collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to optimize CAR designs for cellular therapy.

Key Points: 
  • Serotiny, a leader in high-throughput therapeutic Multi-Domain Protein (tMDP) engineering, announced today a collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to optimize CAR designs for cellular therapy.
  • Were excited to be working with Janssen scientists, said Colin Farlow, J.D., Serotinys CEO.
  • Serotiny is located at the Johnson & Johnson Innovation JLABS incubator in South San Francisco, CA.
  • Serotiny is a pre-clinical discovery company building better gene and cell therapies through engineering Therapeutic Multi-Domain Proteins (tMDP) such as Chimeric Antigen Receptors (CARs), alternative CARs, accessory proteins and gene editing systems in high-throughput.

Serotiny Appoints Chad May, Ph.D., as Chief Scientific Officer

Retrieved on: 
Monday, May 23, 2022
Oncology, Health, Genetics, General Health, Pharmaceutical, Biotechnology, Cell biology, Knowledge, Engineering, Center for Research and Development in Health Sciences, Doctor of Philosophy, Weill Cornell Graduate School of Medical Sciences, Maverick, Leadership, Patient, Synthetic biology, Medicine, Sloan, Canadian Aviation Regulations, IND, TMDP, Chimeric antigen receptor T cell, Takeda, Protein, University, Technology, Chad, Eli Lilly, Heart, Machine learning, ImClone Systems, Medical device, Vaccine, Immunology, Serotiny, Research, Pfizer, Genetics

Serotiny, a leader in high-throughput therapeutic Multi-Domain Protein (tMDP) engineering for the next generation of cell and gene therapies, has appointed Chad May, Ph.D., as the company's Chief Scientific Officer.

Key Points: 
  • Serotiny, a leader in high-throughput therapeutic Multi-Domain Protein (tMDP) engineering for the next generation of cell and gene therapies, has appointed Chad May, Ph.D., as the company's Chief Scientific Officer.
  • In this new role, Dr. May will lead the research and development of Serotinys novel therapeutics programs.
  • "Chad is a fantastic addition to the Serotiny leadership team," said Serotiny Chief Executive Officer Colin Farlow.
  • Dr. May commented, "It is very exciting for me to be joining the innovative team at Serotiny.

Serotiny and Tessera Therapeutics enter into collaboration to engineer and optimize programmable Gene Writer proteins

Retrieved on: 
Monday, February 28, 2022
Other Health, Research, General Health, Professional Services, Pharmaceutical, Venture Capital, Medical Devices, Genetics, Science, Biotechnology, Other Science, Health, Geoffrey von Maltzahn, Health, Mobile genetic elements, Gene, Chimeric antigen receptor T cell, Efficiency, RNA, Protein, Reverse transcriptase, RNA transfection, TMDP, CAR, Therapy, Genome, Flagship Pioneering, Heart, Canadian Aviation Regulations, Machine learning, DNA, MGE, Biotechnology, Recombinase, Integrase, Engineering, Technology, Synthetic biology, Patient, Mining, CEO, Research, Doctor of Philosophy, Vaccine, Antibiotics, Serotiny, Tessera, Serotiny, Tessera’s Gene Writer platform, Tessera Therapeutics, SEROTINY, TESSERA’S GENE WRITER PLATFORM, TESSERA THERAPEUTICS

Serotiny, a leader in high-throughput therapeutic Multi-Domain Protein (tMDP) engineering, and Tessera Therapeutics, a biotechnology company pioneering a new approach in genetic medicines known as Gene Writing technology, today announced a collaboration to engineer programmable Gene Writer proteins.

Key Points: 
  • Serotiny, a leader in high-throughput therapeutic Multi-Domain Protein (tMDP) engineering, and Tessera Therapeutics, a biotechnology company pioneering a new approach in genetic medicines known as Gene Writing technology, today announced a collaboration to engineer programmable Gene Writer proteins.
  • This collaboration will build on Tesseras innovations in genome engineering technologies and apply Serotinys tMDP mining and design expertise to further optimize Tesseras programmable Gene Writer proteins, capable of making diverse and directed alterations to the genome.
  • By partnering with Serotiny, Tessera will have the ability to identify, screen, and optimize a variety of proteins that can serve as the foundation of future Gene Writer therapies across a variety of disease states.
  • Serotinys multi-domain engineering expertise has the potential to further optimize our Gene Writer protein libraries and were delighted to partner with the Serotiny team.